If you experience nausea beyond the initial period of treatment, talk to your healthcare provider
These convergent changes suggest that Retatrutides effects on cognition may involve mechanisms extending beyond peripheral metabolic regulation, potentially including modulation of inflammatory and neurotrophic-related pathways
This process keeps food in the digestive system for longer making people feel fuller for longer, thus reducing appetite and inducing weight loss
A phase 3 clinical trial for retatrutide is currently underway and expected to wrap up in May 2026
These may include: Nausea (affecting approximately 20-40% of patients, depending on the specific medication) [17] Mild abdominal discomfort or bloating Changes in bowel habits , including constipation or occasionally diarrhoea Reduced appetite , which whilst therapeutic, can feel unusual initially These effects are generally mild to moderate and tend to improve as the body adjusts to the medication, typically within 24 weeks
Recent advances in peptide-based therapies for obesity and type 2 diabetes
